153 related articles for article (PubMed ID: 38015944)
21. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
22. Lung cancer histology classification from CT images based on radiomics and deep learning models.
Marentakis P; Karaiskos P; Kouloulias V; Kelekis N; Argentos S; Oikonomopoulos N; Loukas C
Med Biol Eng Comput; 2021 Jan; 59(1):215-226. PubMed ID: 33411267
[TBL] [Abstract][Full Text] [Related]
23. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
[TBL] [Abstract][Full Text] [Related]
24. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
26. Tumour volume changes assessed with high-quality KVCT in lung cancer patients undergoing concurrent chemoradiotherapy.
Lee YH; Kim YS; Lee HC; Lee SW; Kang YN; Kang JH; Hong SH; Kim YK; Kim SJ; Ahn MI; Han DH; Yoo IR; Park JG; Sung SW; Lee KY
Br J Radiol; 2015 Aug; 88(1052):20150156. PubMed ID: 26055505
[TBL] [Abstract][Full Text] [Related]
27. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.
Huang W; Zhou T; Ma L; Sun H; Gong H; Wang J; Yu J; Li B
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1628-35. PubMed ID: 21617977
[TBL] [Abstract][Full Text] [Related]
28.
Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310
[TBL] [Abstract][Full Text] [Related]
29. 3D convolutional neural network model from contrast-enhanced CT to predict spread through air spaces in non-small cell lung cancer.
Tao J; Liang C; Yin K; Fang J; Chen B; Wang Z; Lan X; Zhang J
Diagn Interv Imaging; 2022 Nov; 103(11):535-544. PubMed ID: 35773100
[TBL] [Abstract][Full Text] [Related]
30. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
31. Pre- and postoperative care for stage I-III NSCLC: Which quality of care indicators are evidence-based?
Numan RC; Berge MT; Burgers JA; Klomp HM; van Sandick JW; Baas P; Wouters MW
Lung Cancer; 2016 Nov; 101():120-128. PubMed ID: 27794400
[TBL] [Abstract][Full Text] [Related]
32. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
33. The value of nodal information in predicting lung cancer relapse using 4DPET/4DCT.
Li H; Becker N; Raman S; Chan TC; Bissonnette JP
Med Phys; 2015 Aug; 42(8):4727-33. PubMed ID: 26233200
[TBL] [Abstract][Full Text] [Related]
34. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
35. Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.
Agrawal V; Coroller TP; Hou Y; Lee SW; Romano JL; Baldini EH; Chen AB; Jackman DM; Kozono D; Swanson SJ; Wee JO; Aerts HJ; Mak RH
Lung Cancer; 2016 Dec; 102():1-8. PubMed ID: 27987576
[TBL] [Abstract][Full Text] [Related]
36. Effect of radiologic stage III substage on nonsurgical therapy of non-small cell lung cancer.
Kreisman H; Lisbona A; Olson L; Propert KJ; Modeas C; Dillman RO; Seagren SL; Green MR
Cancer; 1993 Sep; 72(5):1588-96. PubMed ID: 8394201
[TBL] [Abstract][Full Text] [Related]
37. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
[No Abstract] [Full Text] [Related]
38. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer.
Blanc-Durand P; Campedel L; Mule S; Jegou S; Luciani A; Pigneur F; Itti E
Eur Radiol; 2020 Jun; 30(6):3528-3537. PubMed ID: 32055950
[TBL] [Abstract][Full Text] [Related]
40. Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy.
Hwang SH; Yoo MR; Park CH; Jeon TJ; Kim SJ; Kim TH
Eur Radiol; 2013 Jun; 23(6):1573-81. PubMed ID: 23300040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
